BenzingaAugust 25, 2026 at 5:32 AM NY10 days ago
RBC Capital Maintains Outperform on Biogen, Raises Price Target to $260
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $240 to $260.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Yahoo5 hours ago
Which dow jones stocks are moving on Friday?
ChartMill1 hour ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill1 hour ago
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo2 hours ago
Sector Update: Financial
Yahoo3 hours ago